Format

Send to

Choose Destination
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 5;43(0):E002. doi: 10.3760/cma.j.issn.1001-0939.2020.0002. [Epub ahead of print]

[Potential antiviral therapeutics for 2019 Novel Coronavirus].

[Article in Chinese; Abstract available in Chinese from the publisher]

Author information

1
Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020, China.
2
Department of Basic Medical Sciences, Tsinghua University School of Medicine, Beijing 100084, China.

Abstract

in English, Chinese

The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains - severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir / ritonavir, lopinavir / ritonavir combined with interferon-β, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials.

KEYWORDS:

2019 novel coronavirus; Antiviral therapy; Infection

Supplemental Content

Full text links

Icon for Chinese Medical Association Publishing House Ltd.
Loading ...
Support Center